Expertise in
17
conditions

Dr. Hans Lee

Hematology
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 
Expertise in
17
conditions
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 

Overview

Hans Lee is a Hematologist in Cary, North Carolina. Dr. Lee is highly rated in 17 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Plasmacytoma, Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 165 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in MO

Hospital Affiliations

Tristar Centennial Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PacificSource
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

UT MD Anderson Cancer Center
210 Ashville Ave # 408, Cary, NC 27518
Other Locations
Office
335 24th Ave N Ste 200, Nashville, TN 37203

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination With Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination With Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
Enrollment Status: Terminated
Publish Date: February 10, 2026
Intervention Type: Procedure, Drug
Study Drugs: Carfilzomib, Dexamethasone, Dexamethasone Sodium Phosphate, Lenalidomide, MDM2 Inhibitor KRT-232
Study Phase: Phase 1
A Phase 2 Study of Daratumumab, Bortezomib, and Dexamethasone (DVd), Followed by Daratumumab, Ixazomib, and Dexamethasone (DId) for Relapsed and/or Refractory Myeloma
A Phase 2 Study of Daratumumab, Bortezomib, and Dexamethasone (DVd), Followed by Daratumumab, Ixazomib, and Dexamethasone (DId) for Relapsed and/or Refractory Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Bortezomib, Daratumumab, Dexamethasone, Ixazomib
Study Phase: Phase 2
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
Enrollment Status: Completed
Publish Date: September 03, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin Frozen Liquid, Belantamab Mafodotin Lyophilized Powder
Study Phase: Phase 2
A Safety Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
A Safety Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2025
Intervention Type: Biological, Drug
Study Drugs: Daratumumab, Dexamethasone, Ixazomib
Study Phase: Phase 1
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
Enrollment Status: Completed
Publish Date: April 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
Enrollment Status: Terminated
Publish Date: March 26, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

165 Total Publications

Costs per responder for patients with relapsed or refractory multiple myeloma treated with Talquetamab compared with usual care.
Costs per responder for patients with relapsed or refractory multiple myeloma treated with Talquetamab compared with usual care.
Journal: Journal of medical economics
Published: January 03, 2026
Similar Doctors
Expertise in
39
conditions
Dr. Tapan Kadia
Hematology
Expertise in
39
conditions
Dr. Tapan Kadia
Hematology

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (449.3 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tapan Kadia is a Hematologist in Cary, North Carolina. Dr. Kadia is highly rated in 39 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Prolymphocytic Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
32
conditions
Dr. Prithviraj Bose
Hematology
Expertise in
32
conditions
Dr. Prithviraj Bose
Hematology

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (449.3 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Prithviraj Bose is a Hematologist in Cary, North Carolina. Dr. Bose is highly rated in 32 conditions, according to our data. His top areas of expertise are Myelofibrosis, Essential Thrombocythemia, Myeloproliferative Neoplasms (MPN), Bone Marrow Aspiration, and Bone Marrow Transplant.

Richard Champlin
Expertise in
30
conditions
Dr. Richard Champlin
Hematology
Expertise in
30
conditions
Dr. Richard Champlin
Hematology

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (449.3 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances

Richard Champlin is a Hematologist in Cary, North Carolina. Dr. Champlin is highly rated in 30 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Hans Lee

How do I make an appointment with Dr. Hans Lee?

You can book an appointment with Dr. Hans Lee by calling their office at 713-792-6161. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Hans Lee a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Hans Lee is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Hans Lee specialize in?

While Dr. Hans Lee is a Hematology, they have specific expertise in Multiple Myeloma, Plasmacytoma, and Smoldering Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Hans Lee participate in research or clinical trials?

Yes. Dr. Hans Lee has published 165 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Hans Lee's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Hans Lee accept my insurance?

Dr. Hans Lee accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 713-792-6161 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lee's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile